Applied DNA Sciences Up 37% (APDN)

Shares of microcap company Applied DNA Sciences is changing hands in intraday trading today up 37% (APDN), currently trading at its highs of the day. Interest in Applied DNA Sciences may have increased after Advanced Cell Technology (

) announced on November 22 that it had received FDA approval to begin treating patients as part of the company's Phase I/II Clinical Trial focusing on the treatment Stargardt's Disease, a form of juvenile macular degeneration. A week later, Advanced Cell Technology announced that it has filed an Investigational New Drug [IND] Application with the US Food and Drug Administration [FDA] to initiate a Phase I/II multicenter study using human embryonic stem cells.